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Abstract
Background: Women carrying BRCA-mutations are facing significant challenges, including decision making
regarding surveillance and risk-reducing surgery. They often report that they are left alone with these important
decisions. In order to enhance the genetic counselling session we organized a group-based patient education (GPE)
course for women with BRCA-mutations. The study aims were to characterize women attending a group-based
patient education (GPE) course for hereditary breast and ovarian cancer, consider the usefulness of the course,
evaluate symptoms of anxiety and depression among the participants, and finally investigate whether their levels of
anxiety and depression changed from before to after the course session.
Methods: A prospective study was conducted. Two weeks before (T1) and 2 weeks after (T2) attending the GPE-
course the participants received questionnaires by mail. We collected information on demographic- and medical
variables, anxiety and depression using Hospital Anxiety and Depression Scale (HADS), self-efficacy using The
Bergen Genetic Counseling Self-Efficacy scale (BGCSES) and coping style using the Threatening Medical Situations
Inventory (TMSI). A total of N = 100 (77% response rate) women participated at baseline and 75 (58% response rate)
also completed post-course assessment.
Results: The mean level of anxiety symptoms was elevated among participants but decreased significantly during
follow-up. Lower anxiety symptom levels were associated with “longer time since disclosure of gene test result”,
“higher levels of self-efficacy” and having experienced “loss of a close relative due to breast or ovarian cancer”.
Lower depression symptom levels were associated with “higher levels of education” and “loss of a close relative due
to breast or ovarian cancer”.
Conclusion: The women in this study seemed to benefit from the GPE course. Women newly diagnosed with a
BRCA mutation who reported lower levels of self-efficacy and lower levels of education were more vulnerable.
These women need special attention.
Keywords: Group-based patient education course, Genetic counseling, Hereditary cancer, Anxiety symptoms,
Depression symptoms
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Background
Carriers of mutations in the BRCA1- or BRCA2 gene
(breast cancer genes) have a substantially increased
risk of both breast and ovarian cancer. The cumulative
risk for breast cancer by age 70 has been reported to
45–60% for BRCA1 mutation carriers and 27–55% for
BRCA2 mutation carriers with a corresponding risk
for ovarian cancer of 31–59% and 6–16.5% for BRCA1
and BRCA2 mutation carriers, respectively [1, 2]. Be-
ginning at age 25, women with a mutation in either of
these genes are offered breast cancer surveillance, in-
cluding annual mammography and breast magnetic
resonance imaging (MRI). Between 35 and 40 years,
risk-reducing salpingo-oophorectomy is recommended
[3, 4]. A growing number of women are also opting
for risk-reducing bilateral mastectomy [5–8]. Deci-
sions to have risk-reducing surgeries are both irrevers-
ible and existential in nature; they are also associated
with both psychosocial burden as well as hope for a
longer and healthier life [3, 9, 10].
Genetic counseling is a specialized healthcare service
provided by specialists in medical genetics and genetic
counselors. It is described as a communication and edu-
cational process that deals with the challenges associated
with the occurrence, or the risk of occurrence, of a gen-
etic disorder within a family [11]. In the counseling ses-
sion, it is important to impart information that provides
the basis for informed decisions regarding gene testing,
surveillance programs, and prophylactic surgery. It is
also critical to acknowledge that the genetic information
may have a significant impact on the patient’s extended
family. The counseling session may trigger ethical di-
lemmas such as whom should be informed and when
the best time may be to pass on the genetic information
to children and other family members [6, 12]. Thus, pa-
tients need proper counseling and follow-up to make de-
cisions related to these aspects [13]. Genetic counseling
is often a one-on-one consultation. Previous research
has shown that group-based patient education (GPE)
courses are valuable toward empowered decision-
making among women [14–17] and may serve as a use-
ful supplement to traditional individual counseling.
Over the past decades, several studies have focused on
emotional distress among patients seeking genetic coun-
seling for hereditary cancer [6, 12, 18]. Anxiety is a nor-
mal reaction to a stressor. It is most often described as
the emotion of fear involving feelings of tension, ner-
vousness, apprehension, worry and dread for something
perceived as threatening in the future [19]. Mild to mod-
erate anxiety symptoms are vague and unsettling, while
severe anxiety symptoms can be extreme and have a ser-
ious impact on daily life. Depression has been defined as
an emotion of sadness, with feelings of sorrow, hopeless-
ness, gloom, lack of energy and initiative [20]. Anxiety
and depression are different conditions, but they com-
monly occur together [21].
Many factors influence a BRCA mutation carrier’s anx-
iety and depression levels. Earlier studies have shown that
younger age, having children, and experience of breast
and ovarian cancer among close relatives are strong pre-
dictors of high emotional distress [22, 23]. Self-efficacy
and social support seem to play important roles in redu-
cing anxiety and depression levels among patients at risk
for hereditary cancer [18]. Previous studies revealed that
patients are often satisfied with genetic counseling ses-
sions [24, 25]. Providing medical information and emo-
tional support appears to be important for increasing
patients’ satisfaction [12, 26]. Several studies have also
shown that a monitoring coping style is related to reduced
psychological distress in genetic counseling for hereditary
cancer [27, 28]. Other studies have shown that some indi-
viduals need additional counseling or different interven-
tions such as GPE courses [14–17, 25, 29].
Patient education is a major task for healthcare
workers and is incorporated in formal legislation or reg-
ulations in several countries [30, 31]. Educating patients
and their significant others is considered a part of pa-
tient treatment and has been proven to increase compli-
ance with treatment [32]. Learning and Mastery Centers
have been established to support the health services with
education courses for both patients and health profes-
sionals [33]. Previous research indicates a positive effect
of GPE courses on psychosocial outcomes such as men-
tal health, coping, and knowledge about their illness [32,
34–36]. Group intervention appears to be relevant and
highly acceptable to women with a mutation in one of
the BRCA genes [8, 16, 17]. Participating in a patient
education group seems to help these women make can-
cer risk management decisions [37]. GPE for BRCA mu-
tation carriers may be the ideal forum for exploring
challenges, such as when to share genetic information
with the extended family and dealing with the guilt of
having passed the mutation on to their children [16].
Interacting with other women with a BRCA mutation
also gives patients the opportunity to learn from each
other and reinforces a feeling of not being alone [14].
The main goal of the study was to describe the BRCA
mutation carriers who attended a GPE course. We also
investigated whether the GPE course was experienced as
a useful intervention for these women. Finally, we evalu-
ated the characteristics of those with increased levels of
anxiety or depression symptoms and whether these
symptoms changed from before the course until after.
Methods
Study design and procedures
A prospective study was undertaken in women with
BRCA mutations who took part in a GPE course. Two
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weeks before attending the course, the women received
written information about the study, were invited to pro-
vide written informed consent and were provided with
the first questionnaires (T1). Two weeks after the course
(T2), follow-up questionnaires were mailed to those who
had provided written informed consent. The Data
Protection Official for Haukeland University Hospital
approved the study.
Study sample
From October 2011 to August 2013, eight GPE courses
were arranged. Both healthy women and women with a
personal history of cancer were invited to participate in
a course if they fulfilled the following inclusion criteria:
over 18 years old, able to read Norwegian, had been to
genetic counseling for hereditary breast and ovarian can-
cer, and were carrying a BRCA mutation. Of the 160
women invited, 130 signed up for a GPE course and re-
ceived a confirmation phone call from the staff at the
Center for Medical Genetics, Haukeland University
Hospital.
The group-based patient education (GPE) course
To meet the women’s needs for psychosocial support
after genetic counseling and a positive BRCA test result,
our GPE course was based on earlier proposals from
groups associated with the Norwegian Cancer Society.
The GPE course was standardized to a seven-hour ses-
sion, with a maximum of 20 participants in each course.
The primary aims of the course were to support and em-
power participants to live their lives and make decisions
based on information and advice from health profes-
sionals, and to provide the opportunity for them to learn
from each other. We incorporated a strong user perspec-
tive in the planning, implementation, and evaluation of
the GPE course. This ensured that the users’ voice was
heard and increased the chances of keeping the course
patient-focused [33]. See Table 1 for an overview of the
themes included in the GPE course.
Study measurements
Sociodemographic and medical variables
The sociodemographic and medical variables included:
age, marital status, children, education, cancer or an-
other chronic disease, and time since the genetic test
was carried out. We also collected family history of
breast and ovarian cancer and asked whether the re-
spondents had experienced loss of significant others.
Standardized evaluation following the GPE course
We used a standardized evaluation developed by the
Norwegian National Advisory Unit on Learning and
Mastery in Health. It is designed to support quality im-
provement (NK LMH 2009).
Situation specific self-efficacy
The Bergen Genetic Counseling Self-efficacy Scale
(BGCSES) was developed according to Bandura’s guide-
lines for constructing self-efficacy scales (revised 2001)
(Albert Bandura, Stanford University Palo Alto, CA,
USA). According to Bandura self-efficacy is a person’s
beliefs in own ability to cope with different challenges
and to execute some control over environmental
events. It was developed by a panel of medical geneti-
cists, genetic counselors and psychologists [18]. The
scale consists of 20 items describing tasks and chal-
lenges likely to occur during a GPE course, and the in-
dividual’s belief in their ability to cope with different
challenges. Each item is rated on a scale from 1 (cannot
do at all) to 11 (can do without difficulty). The average
score of BGCSES for each individual (range 1–11) was
used in the present study. Higher scores indicate higher
self-efficacy. The reliability of the scale, estimated by
Cronbach’s alpha, was 0.85.
Symptoms of anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) was
used to assess symptoms of anxiety and depression. The
questionnaire has two subscales each with seven items
that measure symptoms of anxiety and depression, re-
spectively. Each item is scored on a four-point scale.
Each total subscale score ranges from 0 to 21 [38]. A
score of eight or higher was used as the cut-off for ele-
vated symptoms of both anxiety and depression [39]. In
the present study, reliability values for the HADS anxiety
and depression subscales, estimated with Cronbach’s
alpha, were 0.87 and 0.84, respectively.
Coping style
The Threatening Medical Situation Inventory (TMSI)
was used to measure two cognitive coping styles in the
domain of medical threat: monitoring (confrontation
style) and blunting (avoidance style). The TMSI includes
Table 1 Thematic overview of the GPE course
• User perspective of a women carrying a BRCA mutation who is an
“expert by experience” a
• General information about hereditary breast and ovarian cancers and
the consequences of being a mutation carrier, including the family
perspective
• Information about risk-reducing bilateral salpingo-oophorectomy and
hormone replacement therapy
• Medical information about prophylactic bilateral mastectomy
• Discussions about body image and sexuality
• Information from patient networking groups
• Interaction between the course participants in small groups, which
gives them an opportunity to learn from each other and reinforce a
feeling of not being alone
a “Expert by experience”: a BRCA carrier who received her gene test results
several years ago
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four descriptions of threatening medical situations. Each
TMSI situation is followed by three monitoring and
three blunting items, arranged in random order, which
are scored on a five-points scale from 1 (not at all ap-
plicable to me) to 5 (strongly applicable to me). Total
monitoring and blunting scores were calculated by sum-
ming the relevant items. Ranges for each subscale are
12–60 [40]. Consistent with several other studies, in the
present study we used only the monitoring subscale [27,
41]. Reliability of the TMSI monitoring subscale, esti-
mated by Cronbach’s alpha, was 0.79.
Statistical analyses
Descriptive statistics were used to describe the distribu-
tions of the socio-demographic and medical variables
(i.e. the mean, standard deviation (SD) and proportions).
Paired-sample t-tests were used to compare means of re-
peated measurements and changes in values for anxiety
and depression symptom subscores were analyzed with
McNemar’s exact test. To test for differences between
the final study sample and those who dropped out from
T1 to T2, we used an independent t-test for continuous
variables, and for categorical variables we calculated the
Fisher’s exact mid p-value [42].
To identify the characteristics related to HADS anxiety
and HADS depression, the subscale scores were
regressed on the selected predictor variables using a
mixed linear model module. The mixed linear model
uses all available data and can account for correlations
between repeated measurements on the same subjects
and has sufficient flexibility to model time effects [43].
All predictors were entered into the mixed linear models
to assess both their main effects and their possible inter-
actions with time. The regression analyses were run
backwards stepwise, both with and without interaction
with time.
Missing values were replaced according to the guide-
lines for each instrument or by the individual’s own aver-
age score for each questionnaire when more than 50% of
the items were completed. Reliability was estimated by
Cronbach’s alpha for all scales used in this study. A two-
tailed significance level of 0.05 was used. All data were
analyzed using SPSS version 22.
Results
The study sample and characteristics of predictor
variables
Of the 130 eligible women, 100 (77%) consented to the
study and returned their questionnaires at baseline, and
75 (58%) completed both questionnaires. We have no
data on the 30 non-responses. Characteristics of socio-
demographic and medical variables for the study sample
are provided in Table 2. The mean age of the study sam-
ple was 45.8 years (range: 26–69 years) and the mean
time since they received the BRCA test results was 5.3
years (range: 1 month–15 years). About 87% were co-
habiting, 87% had children, and 89% reported their edu-
cation level to be high school or above. Among the
participants, 26% had a personal history of cancer. The
majority of the samples had experienced cancer and
death among their close relatives. The participants re-
ported both high situation specific self-efficacy and high
average score for monitoring coping style (Table 3).
On average, the respondents reported that they were
satisfied with the GPE course. Each theme in the GPE
course was scored on a five-point scale from 1 (“not im-
portant”) to 5 (“very important”). The average score for
all themes was 3.84 (SD: 0.08). Of the 75 women who
responded to the follow-up questionnaires, 41.3% re-
ported that the intervention was “good”, and the rest
(58.7%) reported it went “very well”. None of the partici-
pants indicated that they were dissatisfied with the GPE
course. A majority of the women, 75.7%, reported that
they had learned something new. However, 34.7% re-
ported that they missed something and 33.3% were un-
sure if they missed important topics.
Drop-outs
Drop-outs were defined as having responded at T1 but
not at T2. Drop-outs (25%) were significantly younger,
with a mean age of 40.0 years compared to 47.7 years
among the complete study sample (p = 0.005). There
were also significantly more drop-outs who reported
having “no children” (p = 0.026). Otherwise, the drop-
outs did not differ on any of the other study variables
(Table 2).
Outcome variable: anxiety (HADS-A) and depression
(HADS-D)
Mean score, SDs, and numbers of individuals with
symptom scores for anxiety and depression above the
cut-off values are provided in Table 3. The mean HADS
subscale score for anxiety was 6.2 (SD: 4.14) at T1, with
a significant decrease to 5.2 (SD: 3.95) at T2 (p = 0.003).
The mean HADS-D subscale score was 2.8 (SD: 3.33)
and did not change significantly from T1 to T2. The
number of participants with scores above the cut-off
level of HADS-A dropped from T1 to T2 but the de-
crease was not statistically significant (p = 0.065). The
proportion of individuals with a HADS-D score above
the cut-off level did not change significantly from T1 to
T2 (Table 3).
Mixed linear model analysis of anxiety and depression
symptoms
The following predictors were used: age, having children,
cohabiting status, educational status, having cancer, ex-
periencing the death due to breast or ovarian cancer of a
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first-degree and/or second-degree relative, time since
disclosure of the gene test results, monitoring coping
style, and situation specific self-efficacy.
The results of the mixed linear model analyzed for
HADS-A are provided in Table 4. The final model of the
mixed linear model showed that the average level of
anxiety symptoms varied with time and that the highest
levels were at T1. Anxiety symptom levels decreased
with greater time since disclosure of the gene test result,
a higher level of situation specific self-efficacy, and if the
women had experienced losing a first and/or second-
degree relative due to breast or ovarian cancer.
The final model of the mixed linear model analyzed
for HADS-D is provided in Table 5. In contrast, the
average level of depression symptoms did not change
from T1 to T2. However, a lower depression score was
related to a higher level of education and to having
experienced death related to breast and/or ovarian can-
cer among a first and/or second-degree relative.
Discussion
The mean level of anxiety symptoms among our partici-
pants was higher (6.2) compared with earlier studies
among women undergoing genetic counseling for her-
editary cancer (5.0) [18]. However, the level decreased
significantly by post-GPE follow-up, while the mean
level of depression symptoms was low and stable
throughout the study period. One of the main findings
from this study was that lower symptoms of anxiety
were associated with longer time since disclosure of the
gene test results, higher levels of self-efficacy and having
experienced the death of a close relative due to breast or
ovarian cancer. While a higher level of education and
experienced the death of a close relative due to breast or
Table 2 Sociodemographic and medical characteristics of women attending group-based patient education (GPE) course
Characteristic Respondents (n = 100) Drop-outsa
(n = 25)
Category n % n % p-value
Marital status 0.083b
Married/cohabiting 87 87.0 19 21.8
Living alone 13 13.0 6 3.3
Children 0.026b
Yes 87 87.0 20 21.8
No 13 13.0 5 3.3
Educational status 0.501c
Primary school 11 11.0 1 2.8
High school 39 39.0 11 9.8
University 50 50.0 13 12.5
Breast cancer or ovarian cancer 0.451b
Yes 26 26.0 5 6.5
No 74 74.0 20 18.5
FDR and/or SDR died due to BOC 0.643b
Yes 83 83.0 20 20.8
No 17 17.0 5 4.3
Loss of significant others 0.785b
Yes 64 64.0 15 16.0
No 36 36.0 10 9.0
mean (SD) mean (SD) p-valued
Age, years 47.7 (12.6) 39.9 (8.2) 0.005
Years since received BRCA1 or BRCA2 mutation result 5.0 (4.4) 6.3 (3.9) 0.182
HADS anxiety (range: 0–21) 6.1 (4.3) 6.3 (3.8) 0.814
Abbreviations: FDR first degree relative, SDR second degree relative, BOC Breast or ovarian cancer, SD standard deviation, BRCA1 breast cancer type 1 susceptibility
protein, BRCA2 breast cancer type 2 susceptibility protein, HADS Hospital Anxiety and Depression Scale
a Drop-outs are defined as having answered on baseline questionnaires and not on the follow-up
b Fisher’s exact 2-sided mid-p value (calculated from output of chi-square test)
c Chi-square 2-sided linear-by-linear association test
d Independent samples t-test
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ovarian cancer was associated with a lower level of
depression.
All respondents were satisfied with the GPE course
and a majority reported that their knowledge had in-
creased. This might reflect the quality of the course and
the group setting. Alternatively, these women were self-
selected (after being invited) to attend the course and we
must assume that individuals who are uncomfortable
with group-based courses would not enroll in such an
intervention. This possibility is further enhanced by the
fact that our respondents seemed to be quite resourceful
in the sense that they were highly educated, a majority
cohabitated, they reported high levels of self-efficacy,
and they scored high on monitoring coping style.
The mean levels of anxiety and depression symptoms
were below the cut-off score (≥8) [39] both before and
after attending the GPE course. However, it should be
noted that the mean level of anxiety symptoms in our
sample was quite high compared with the general popu-
lation in Norway (4.3) [44], and significantly higher than
reported in earlier studies of individuals seeking genetic
counseling for hereditary cancer [18]. In the present
study, the level of anxiety symptoms was comparable to
newly diagnosed breast and ovarian cancer patients (6.8)
[45]. Although the mean level of symptoms of anxiety
decreased significantly from baseline to posttest, the
mean level at posttest was still similar to other cancer
groups [46]. Signing up for a GPE course might also in-
crease the perceived anxiety level at the time, because
the participants may reactivate thoughts and experiences
not fully addressed previously.
The relatively high level of anxiety symptoms observed
in our sample might be explained by the fact that all of
our participants were mutation carriers. Earlier research
has shown that the level of anxiety symptoms after gen-
etic counseling for hereditary cancer is related to a high
level of pre-test anxiety and being a mutation carrier [6,
47]. Others like Reichelt et al. [48] did not find the same
association between being a mutation carrier and in-
creased level of anxiety. However, they found higher
HADS-A among women with cancer disease [48]. We
did not find support for the latter in our regression
model.
The mean time since disclosure of the gene test result
was about 5 years, but this varied a great deal (from 1
month to 15 years). The GPE courses we evaluated in
the present study were the first to be organized in this
health region and many of the eligible participants had
lived with the knowledge of their mutation status for a
long time. Some might miss someone, like a peer, to talk
to about the challenges associated with being a BRCA
mutation carrier. This again could lead to increased anx-
iety symptoms. Earlier research has also shown that
women with BRCA mutations feel alone with their con-
cerns about being a mutation carrier and report that
they want to discuss their challenges with peers and
health professionals [16, 17]. The latter is indeed what
they get in a GPE course and might explain the signifi-
cant reduction in their anxiety symptom levels.
One should also note that our participants reported a
relatively high level of monitoring coping style, which
did not surprise us. After all, these respondents were
highly self-selected and we would expect a monitoring
personality trait to seek and prefer GPE courses such as
ours. Previous studies have shown that individuals with
high monitoring coping style who seek genetic counsel-
ing report higher anxiety before the visit, and that their
level of anxiety decreases after the counseling session
[27]. We might interpret that a person with a high moni-
toring coping style experiences a decrease in anxiety
level when given the extensive information provided
through a GPE course.
The mean depression symptoms score in our sample
was low and stable across the observation period. This
depression level is similar to a Norwegian population
sample and in line with earlier research on genetic coun-
seling [18, 44]. We cannot rule out that one possible ex-
planation of the low depression scores in our study were
caused by a selection bias: all the participants enrolled in
the course after being invited by the medical genetics
department. Common symptoms of depression such as
lack of energy and initiative may reduce the probability
of signing up for a GPE course, and this will subse-
quently favor participants with lower levels of
depression.
The mixed linear model showed that time since dis-
closure of test results and higher levels of efficacy were
associated with a lower level of anxiety symptoms. It has
Table 3 Study measurement and descriptive statistics in
women attending group-based patient education (GPE) course
Measure T1 = 2 weeks before
GPE course
T2 = 2 weeks after
GPE course
N Mean SD % N Mean SD % p-value
HADS-anxiety
(range: 0–21)
100 6.2 4.1 74 5.2 3.9 0.003 a
HADS-A score≥ 8 29 29.0 14 18.9 0.065 b
HADS-depression
(range: 0–21)
100 2.8 3.3 74 2.6 3.2 0.211 a








Abbreviations: SD standard deviation, HADS Hospital Anxiety and Depression
Scale, TMSI Threatening Medical Situations Inventory
a Paired samples t-test
b McNemar’s exact test
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been well established that time since a potentially trau-
matic event is associated with improved psychosocial
outcome. The women in this study had been enrolled in
surveillance programs, some several years previously,
and one may presume that they have adjusted to the
knowledge of their increased cancer risk. The association
between higher levels of self-efficacy and lower anxiety
symptoms is consistent with earlier findings [18]. Self-
efficacy as a psychological resource is associated with
better outcomes in most demanding situations and this
may partly explain the association we revealed. More
specific medical information will give these individuals
Table 5 Mixed linear regression analyses of Hospital Anxiety and Depression Scale, Depression in the study sample
Variables Not adjusted Fully adjusted (n = 97 a) Final model b (n = 100 a)
b 95% CI p-value c b 95% CI p-value c b 95% CI p-value c
Intercept (Depression) 9.98 ( 3.73, 16.22) 0.002 7.26 (5.03, 9.49) < 0.001
Educational status (n = 100) 0.046 0.033 0.013
University −2.45 (−4.44, −0.47) −2.31 (−4.42, −0.19) −2.54 (−4.43, −0.65)
High school −2.36 (−4.40, −0.32) −2.66 (−4.76, -0.56) −2.92 (−4.89, −0.96)
Primary school 0 (reference) 0 (reference) 0 (reference)
Living with someone (n = 100) −0.24 (−2.10, 1.62) 0.797 0.16 (−1.86, 2.17) 0.877
Children (n = 100) 0.84 (−1.01, 2.68) 0.371 0.87 (−1.19,2.92) 0.404
BOC (n = 100) 1.69 (0.32, 3.05) 0.016 0.73 (−0.90, 2.37) 0.374
FDR/SDR dead due to BOC (n = 100) −2.25 (−3.83, −0.67) 0.006 −1.85 (−3.58, −0.13) 0.036 −2.59 (−4.17, −1.01) 0.002
Age per 10 years (n = 100) 0.43 (−0.07, 0.93) 0.094 0.16 (−0.47, 0.79) 0.618
Disclosure gene test results/years (n = 98) −0.11 (−0.25, 0.04) 0.140 −0.11 (−0.25, 0.04) 0.141
Monitoring coping style per 10 (n = 99) −0.33 (−1.17, 0.51) 0.436 −0.11 (−0.93, 0.72) 0.798
Situation specific self-efficacy (n = 100) −0.48 (−0.93, −0.04) 0.035 −0.47 (−0.97, 0.03) 0.064
Time −0.32 (−0.88, 0.24) 0.264 −0.31 (−0.89, 0.28) 0.296
Abbreviations: b estimated regression coefficient, CI confidence interval, FDR first degree relative, SDR second degree relative, BOC Breast or ovarian cancer
a Number of subjects having completed the whole dataset on at least one occasion during the data collection time
b Final model: After backward stepwise selection from fully adjusted model at significance level 0.05
c F-test
Table 4 Mixed linear regression analyses of Hospital Anxiety and Depression Scale, Anxiety in the study sample
Variables Not adjusted Fully adjusted (n = 97 a) Final model b (n = 98a)
b 95% CI p-value c b 95% CI p-valuec b 95% CI p-value c
Intercept (Anxiety) 16.89 (9.45, 24.32) < 0.001 17.91 (13.04, 22.78) < 0.001
Educational status (n = 100) 0.597 0.331
University −1.21 (−3.76, 1.34) −1.23 (−3.73, 1.27)
High school −1.29 (−3.91, 1.32) −1.50 (−3.99, 0.99)
Primary school 0.00 (reference) 0.00 (reference)
Living with someone (n = 100) −0.19 (−2.52, 2.14) 0.872 0.49 (−1.93, 2.90) 0.691
Children (n = 100) 0.30 (−2.02, 2.61) 0.801 1.31 (−1.13, 3.76) 0.289
BOC (n = 100) 1.22 (−0.52, 2.96) 0.167 0.12 (−1.83, 2.06) 0.906
FDR/SDR died due to BOC (n = 100) −2.62 (−4.61, −0.62) 0.011 −2.06 (−4.12, −0.00) 0.050 −2.25 (−4.08, −0.43) 0.016
Age per 10 years (n = 100) 0.03 (−0.61, 0.67) 0.926 0.07 (−0.68, 0.82) 0.862
Disclosure gene test results/years (n = 98) −0.23 (−0.40, −0.05) 0.012 −0.26 (−0.43, −0.09) 0.003 −0.25 (−0.41, −0.09) 0.002
Monitoring coping style per 10 (n = 99) 0.07 (−0.98, 1.12) 0.899 0.35 (−0.63, 1.32) 0.485
Situation specific self-efficacy (n = 100) −1.02 (−1.55, −0.49) < 0.001 −1.10 (−1.70, −0.51) < 0.001 −0.96 (−1.48, −0.45) < 0.001
Time −0.91 (−1.47, −0.35) 0.002 −0.90 (−1.46, −0.33) 0.002 −0.92 (−1.48, −0.35) 0.002
Abbreviations: b estimated regression coefficient, CI confidence interval, FDR first degree relative, SDR second degree relative, BOC Breast or ovarian cancer
a Number of subjects having completed the included variables on at least one occasion during the data collection time
b Final model: After backward stepwise selection from fully adjusted model at significance level 0.05
c F-test
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higher degrees of satisfaction and further reduce their
level of anxiety symptoms [41, 49, 50].
More surprising, we found that having lost a first and/or
second degree relative to cancer seems to be a “buffer” for
both anxiety and depression symptoms. This is inconsist-
ent with earlier findings [22, 23] and may be explained by
the high levels of both self-efficacy and monitoring coping
styles. Those who sign up for a course such as ours are
more likely to have lived through the grieving process and
actively processed it in an adaptive manner. It should be
noted that women who experience having their mother di-
agnosed with breast cancer at a young age, for example,
make decisions regarding genetic evaluation and follow-
up earlier than women without such an experience [8].
Important life experiences like this may motivate patients
to take health preventive actions. As expected, and in
consistency with earlier findings, we also found an associ-
ation between higher education levels and lower levels of
depression symptoms [44].
In the present study, the drop-outs were significantly
younger and fewer of them had children. We know from
earlier studies that younger patients attending genetic
counseling for hereditary cancer are often more anxious
and vulnerable [51] and this may explain why these par-
ticipants tend to drop-out. On the other hand, this
might be because the youngest felt that the course
themes were not relevant to them. A surveillance pro-
gram, prophylactic surgery, and family issues such as
whether their children have inherited their germline mu-
tation may be irrelevant at their current life stage.
Conclusion
The present study revealed that participants in a GPE
course were resourceful in the sense that they had high
levels of education, were cohabiting, were highly self-
efficacious, and had a high monitoring coping style.
Furthermore, the respondents seem to benefit from at-
tending the course which may indicate that the GPE
course has the intended effect, and therefore could be a
valuable supplement to traditional genetic counselling.
Finally, we identified some participants who may be
more vulnerable and therefore should receive greater at-
tention; specifically, those who were newly diagnosed
with a BRCA mutation, who had lower levels of self-
efficacy, or who had lower levels of education. A conse-
quence of these findings should include arranging regu-
lar GPE courses and offering them as part of the genetic
follow-up. In our department, all women carrying a
BRCA mutation are now offered a GPE course within 6–
12 months after disclosure of the gene test results.
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